Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine (Q33827699)

29 July 2017

Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine (English)

1 reference

29 July 2017

personalized medicine

1 reference

4

Roy S Herbst

1 reference

29 July 2017

Xian Zhou

1

1 reference

29 July 2017

Suyu Liu

series ordinal

2

1 reference

29 July 2017

Edward S Kim

series ordinal

3

1 reference

29 July 2017

J Jack Lee

series ordinal

5

1 reference

29 July 2017

1 January 2008

1 reference

29 July 2017

1 reference

29 July 2017

5

1 reference

29 July 2017

3

1 reference

29 July 2017

181-193

1 reference

Drug development in oncology: classical cytotoxics and molecularly targeted agents

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

4 July 2018

Bayesian clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Clinical trials design and treatment tailoring: general principles applied to breast cancer research

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Introduction to Bayesian methods III: use and interpretation of Bayesian tools in design and analysis

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Randomized phase II designs in cancer clinical trials: current status and future directions

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Development of molecular targeted anticancer agents: successes, failures and future directions

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Genomic and proteomic approaches for studying human cancer: prospects for true patient-tailored therapy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

The method of minimization for allocation to clinical trials. a review

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning-as-we-go?

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Adaptive designs for binary treatment responses in phase III clinical trials: controversies and progress

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Randomized play-the-winner clinical trials: review and recommendations

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial

4 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

Ethical issues in oncology biostatistics.

4 July 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508091815

Introduction to Bayesian methods I: measuring the strength of evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508091815

Introduction to Bayesian methods II: fundamental concepts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508091815

Covariate-adjusted adaptive randomization in a sarcoma trial with multi-stage treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508091815

Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508091815

Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1740774508091815

21 January 2018

Adaptive trial design.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5481999

On the efficiency of targeted clinical trials

29 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Unique issues in the development of "targeted" antineoplastic pharmaceutical agents

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Evaluating the efficiency of targeted designs for randomized clinical trials

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18559407

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1177/1740774508091815

1 reference

29 July 2017

1 reference

29 July 2017

1 reference